Larotrectinib
Larotrectinib, sold under the brand name Vitrakvi, is a medication for the treatment of cancer.[1][5][7] It is an inhibitor of tropomyosin kinase receptors TrkA, TrkB, and TrkC.Larotrectinib was initially awarded orphan drug status in 2015, for soft tissue sarcoma, and breakthrough therapy designation in 2016 for the treatment of metastatic solid tumors with NTRK fusion.Several earlier drugs, including pembrolizumab, were eventually approved by the FDA for treatment of specific mutations independent of the type of cancer, but those drugs had been initially developed for specific cancer types.[1] Phase II clinical trials evaluating the drug for efficacy and safety in treating several types of solid tumors are ongoing.